Total Payments
$609,101
2024 Payments
$17,954
Companies
20
Transactions
374
Medicare Patients
466
Medicare Billing
$61,587
Payment Breakdown by Category
Consulting$266,809 (43.8%)
Research$113,647 (18.7%)
Other$95,945 (15.8%)
Travel$75,763 (12.4%)
Education$48,587 (8.0%)
Food & Beverage$8,350 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $266,809 | 57 | 43.8% |
| Unspecified | $113,647 | 87 | 18.7% |
| Travel and Lodging | $75,763 | 61 | 12.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $67,970 | 20 | 11.2% |
| Education | $48,587 | 34 | 8.0% |
| Honoraria | $27,975 | 5 | 4.6% |
| Food and Beverage | $8,350 | 110 | 1.4% |
Payments by Type
General
$495,455
287 transactions
Research
$113,647
87 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharma AG | $96,645 | 38 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $82,009 | 83 | $0 (2024) |
| Horizon Therapeutics plc | $80,143 | 60 | $0 (2023) |
| EMD Serono, Inc. | $73,330 | 8 | $0 (2022) |
| Merck KGaA | $54,170 | 7 | $0 (2023) |
| Celgene Corporation | $46,354 | 26 | $0 (2019) |
| TG Therapeutics, Inc. | $44,734 | 32 | $0 (2024) |
| GENZYME CORPORATION | $31,240 | 23 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $28,393 | 26 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $18,336 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,954 | 22 | F. Hoffmann-La Roche AG ($6,398) |
| 2023 | $90,845 | 49 | Horizon Therapeutics plc ($26,749) |
| 2022 | $61,286 | 43 | Horizon Therapeutics plc ($27,017) |
| 2021 | $91,883 | 51 | Horizon Therapeutics plc ($26,377) |
| 2020 | $52,491 | 19 | Merck KGaA ($30,960) |
| 2019 | $94,880 | 79 | Novartis Pharma AG ($27,800) |
| 2018 | $144,669 | 63 | EMD Serono, Inc. ($49,200) |
| 2017 | $55,093 | 48 | Novartis Pharmaceuticals Corporation ($17,547) |
All Payment Transactions
374 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $293.27 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 12/13/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Consulting Fee | Cash or cash equivalent | $2,363.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Neurology | ||||||
| 11/19/2024 | Novartis Pharma AG | GILENYA (Drug) | Consulting Fee | Cash or cash equivalent | $638.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $4,091.74 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,582.25 | Research |
| Study: Ocrelizumab in Patients with RMS • Category: Immunology | ||||||
| 09/20/2024 | GENZYME CORPORATION | — | — | In-kind items and services | $500.00 | Research |
| 09/04/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $31.69 | General |
| Category: Neurology | ||||||
| 08/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $91.85 | General |
| Category: Inflammation/Rare Disease | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $430.58 | Research |
| Study: Ocrelizumab treatment and risk for composite disability progression in non-Hispanic Black and Hispanic or Latino individuals by self-identity and genetic ancestry with relapsing multiple sclerosis: findings from the OPERA I and II trials • Category: Immunology | ||||||
| 06/26/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $31.69 | General |
| Category: Neurology | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $140.00 | General |
| 05/31/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $41.61 | General |
| Category: Rare Disease | ||||||
| 05/31/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $29.74 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/31/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $103.90 | General |
| 05/28/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | — | In-kind items and services | $1,604.64 | Research |
| Study: RMS302 • Category: Immunology | ||||||
| 05/28/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | — | In-kind items and services | $837.22 | Research |
| Study: RMS301 • Category: Immunology | ||||||
| 04/13/2024 | Amgen Inc. | UPLIZNA (Biological) | — | In-kind items and services | $84.38 | Research |
| Study: Matching-Adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-Term Effectiveness • Category: Inflammation/Rare Disease | ||||||
| 03/18/2024 | Hexal AG | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 03/11/2024 | Hexal AG | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 03/01/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 12/31/2023 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,759.67 | Research |
| Study: Cerebrospinal fluid neurofilament heavy levels correlate with spinal cord lesions and disability in multiple sclerosis • Category: Immunology | ||||||
| 12/07/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $4.30 | General |
| 12/01/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $10,034.70 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $15,365 | 19 |
| RPC01-201 - A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of | Celgene Corporation | $12,446 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $10,811 | 18 |
| RMS301 | TG THERAPEUTICS, INC. | $8,625 | 3 |
| RPC01-301 - A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclero | Celgene Corporation | $7,261 | 1 |
| Ocrelizumab in Patients with RMS | F. Hoffmann-La Roche AG | $5,967 | 3 |
| CFTY720DS4897354 | Novartis Pharma AG | $5,249 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $4,863 | 9 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $4,375 | 1 |
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients (RPC01-201) | Celgene Corporation | $4,294 | 1 |
| RMS302 | TG THERAPEUTICS, INC. | $3,881 | 2 |
| Publication support research related | Novartis Pharma AG | $3,505 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients (RPC01-301) | Celgene Corporation | $3,342 | 1 |
| RMS302 | TG Therapeutics, Inc. | $2,870 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,415 | 1 |
| RMS301 | TG Therapeutics, Inc. | $2,103 | 4 |
| RPC01-201-PartA | Celgene Corporation | $1,880 | 1 |
| A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RMS TO INVESTIGATE CHANGES IN IMMUNE PHENOTYPE BIOMARKERS AFTER TREATMENT WITH 05MG FINGOLIMOD FLUENT | Novartis Pharmaceuticals Corporation | $1,875 | 1 |
| Cerebrospinal fluid neurofilament heavy levels correlate with spinal cord lesions and disability in multiple sclerosis | F. Hoffmann-La Roche AG | $1,760 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED VARIABLE TREATMENT DURATION STUDY EVALUATING THE EFFICACY AND SAFETY OF SIPONIMOD BAF312 IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS | Novartis Pharmaceuticals Corporation | $1,371 | 1 |
| RPC01-301 | Celgene Corporation | $1,251 | 1 |
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis | F. Hoffmann-La Roche AG | $1,187 | 2 |
| A Phase 1 study to characterize the pharmacokinetics and pharmacodynamics of ozanimod following administration of different multiple-dose regimens in healthy adult caucasian and japanese subjects (RPC01-1911) | Celgene Corporation | $1,144 | 1 |
| PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) | Celgene Corporation | $1,144 | 1 |
| RPC01-201-PartA RPC01-301 | Celgene Corporation | $1,071 | 1 |
| RPC01-3001 - PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) | Celgene Corporation | $884.00 | 1 |
| RPC01-201 | Celgene Corporation | $834.00 | 1 |
| RPC01-3201 - PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) | Celgene Corporation | $442.00 | 1 |
| Ocrelizumab treatment and risk for composite disability progression in non-Hispanic Black and Hispanic or Latino individuals by self-identity and genetic ancestry with relapsing multiple sclerosis: findings from the OPERA I and II trials | F. Hoffmann-La Roche AG | $430.58 | 1 |
| RPC01-201-PartB | Celgene Corporation | $417.00 | 1 |
| Matching-Adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-Term Effectiveness | Amgen Inc. | $84.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 162 | 205 | $103,661 | $15,614 |
| 2022 | 1 | 102 | 144 | $111,312 | $15,494 |
| 2021 | 1 | 108 | 177 | $136,821 | $20,270 |
| 2020 | 1 | 94 | 119 | $91,987 | $10,209 |
Total Patients
466
Total Services
645
Medicare Billing
$61,587
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 73 | 97 | $74,981 | $10,081 | 13.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 32 | $18,464 | $2,362 | 12.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 22 | 22 | $2,104 | $1,582 | 75.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $2,992 | $808.28 | 27.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 17 | 32 | $5,120 | $779.63 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 102 | 144 | $111,312 | $15,494 | 13.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 108 | 177 | $136,821 | $20,270 | 14.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 94 | 119 | $91,987 | $10,209 | 11.1% |
About Dr. Bruce Cree, M.D
Dr. Bruce Cree, M.D is a Neurology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477599454.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Cree, M.D has received a total of $609,101 in payments from pharmaceutical and medical device companies, with $17,954 received in 2024. These payments were reported across 374 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($266,809).
As a Medicare-enrolled provider, Cree has provided services to 466 Medicare beneficiaries, totaling 645 services with total Medicare billing of $61,587. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location San Francisco, CA
- Active Since 06/20/2006
- Last Updated 01/30/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1477599454
Products in Payments
- UPLIZNA (Drug) $80,143
- GILENYA (Drug) $48,444
- MAYZENT (Drug) $32,459
- Ozanimod (Drug) $24,481
- BRIUMVI (Drug) $23,063
- OMB157G (Drug) $18,589
- ZEPOSIA (Drug) $18,336
- FTY720D (Drug) $17,258
- Mavenclad (Drug) $15,480
- BAF312A_MAYZENT_NEUROSCIENCE (Drug) $15,318
- FTD_GILENYA_NEUROSCIENCE (Drug) $12,378
- Mavenclad (Biological) $10,250
- RPC-1063 (Drug) $9,924
- Soliris (Drug) $9,535
- Ocrevus (Biological) $9,345
- FTY720D_GILENYA_NEUROSCIENCE (Drug) $8,754
- AUBAGIO (Drug) $8,482
- OCREVUS (Biological) $6,334
- TYSABRI (Biological) $6,082
- RPC1063 (Drug) $5,036
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in San Francisco
Dr. Scott Zamvil, Md, MD
Neurology — Payments: $591,541
Neurology $591,541
Dr. S Claiborne Johnston, M.d, M.D
Neurology — Payments: $545,407
Neurology $545,407
Dr. Douglas Goodin
Neurology — Payments: $467,336
Neurology $467,336
Mr. Kenneth Laxer, M.d, M.D
Neurology — Payments: $419,550
Neurology $419,550
Dr. Armen Moughamian, Md, MD
Neurology — Payments: $333,078
Neurology $333,078
Nada Hindiyeh
Neurology — Payments: $322,416
Neurology $322,416